 "Suven Life Sciences rallies on securing product patents")
Suven Life Sciences has rallied nearly 6% to Rs 245 on the BSE after the company announced it secures three product patents two from Canada and one from China for a drug used in the treatment of neuro-degenerative diseases.
The patents are valid until 2029 and 2030, respectively, Suven Life Sciences said in a filing to the BSE.
“The company grant of two product patents from Canada and one product patent from China corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases,” Suven Life Sciences said in a press release.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD), it added.
At 10:34 a.m. the stock was up 4% at Rs 242 on the BSE. A combined 1.22 million shares changed hands on the counter on the BSE and NSE.
The patents are valid until 2029 and 2030, respectively, Suven Life Sciences said in a filing to the BSE.
“The company grant of two product patents from Canada and one product patent from China corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases,” Suven Life Sciences said in a press release.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD), it added.
At 10:34 a.m. the stock was up 4% at Rs 242 on the BSE. A combined 1.22 million shares changed hands on the counter on the BSE and NSE.